Immunic (NASDAQ:IMUX) Shares Up 0.7% – Here’s Why

Immunic, Inc. (NASDAQ:IMUX)’s share price rose 0.7% during mid-day trading on Monday . The stock traded as high as $15.78 and last traded at $15.41. 358,011 shares changed hands during mid-day trading, an increase of 73% from the average session volume of 206,803 shares. The stock had previously closed at $15.30.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IMUX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. HC Wainwright restated a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research report on Sunday, April 19th. Lifesci Capital upgraded Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Finally, Stifel Nicolaus set a $25.00 price target on Immunic and gave the stock a “buy” rating in a research note on Thursday, April 16th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $47.57.

Immunic Price Performance

The firm has a market cap of $209.88 million, a PE ratio of -2.76 and a beta of 1.37. The business has a fifty day moving average price of $12.56 and a two-hundred day moving average price of $10.06.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.37). As a group, sell-side analysts forecast that Immunic, Inc. will post -4.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Avidity Partners Management LP lifted its position in Immunic by 42.6% in the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after buying an additional 2,000,000 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new position in shares of Immunic in the first quarter worth $27,000. Bank of America Corp DE increased its stake in shares of Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after acquiring an additional 143,689 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Immunic during the first quarter worth $33,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Immunic during the first quarter worth $187,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.